The 8 most recent market catalysts affecting $BNGO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 75
Bionano Says Memorial Sloan Kettering Expands Blood Cancer Testing Using Its Optical Genome Mapping After New York State Approval
The expansion of Bionano's optical genome mapping by Memorial Sloan Kettering, following New York State approval, is a strong validation of their Saphyr system. This move suggests …
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
Bionano Genomics Stock Surges Tuesday: What's Going On?
Bionano Genomics' stock surged following its presentation at the H.C. Wainwright conference, where management outlined a multi-year growth strategy projecting substantial revenue i…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Genomics' subsidiary, Bionano Laboratories, announced that MolDX, a Medicare program, has issued a proposed Local Coverage Determination (LCD) for genome-wide molecular met…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
Bionano Genomics Says New York State Department Of Health Approved Optical Genome Mapping Lab Developed Tests At University Of Rochester Medicine For Genetic Disorders, Hematologic Malignancies
The New York State Department of Health's approval of Bionano Genomics' optical genome mapping (OGM) lab-developed tests at the University of Rochester Medicine is a major positive…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Bionano Genomics Q2 EPS $(0.64) Beats $(0.69) Estimate, Sales $8.171M Beat $7.476M Estimate
This headline is a positive corporate catalyst for Bionano Genomics (BNGO). Beating both EPS and sales estimates suggests better-than-anticipated execution and potentially growing …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est
Bionano Genomics filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The company increased the lower bound of its sales outlook from $30 million to …
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 75
Bionano Genomics Sees Q3 Sales $8.200M-$8.600M vs $8.575M Est
Bionano Genomics (BNGO) announced preliminary Q3 sales guidance, forecasting revenues between $8.2 million and $8.6 million. This range is very close to the analyst consensus estim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.